Recommended Global Psychiatry Webinars & Conferences
Asia Pacific & Middle East
Canada
Euro Dementia-2026
Welcome Note
On behalf of the organizing committee, it is my great honor and privilege to welcome you to the 6th European Conference on Dementia, Alzheimers and Neurological Disorders, taking place on May 21-22, 2026, in the vibrant city of Paris, France.
This premier conference serves as an essential platform for neurologists, neuroscientists, clinicians, researchers, healthcare professionals, and industry pioneers dedicated to combating neurodegenerative diseases such as dementia and Alzheimer’s disease. As the global burden of neurological disorders continues to rise, collaboration and innovation are crucial to accelerate breakthroughs in diagnosis, treatment, and patient care.
Over these two days, we will explore cutting-edge research in neurodegeneration, advances in biomarker discovery, neuroimaging, therapeutic interventions, and the latest developments in cognitive health and neurorehabilitation. This event offers unparalleled opportunities to share knowledge, discuss clinical challenges, and forge collaborations that drive progress in understanding and managing dementia and related neurological disorders.
Our conference theme, “Innovating Minds: Bridging Research and Care for a Dementia-Free Future,” highlights our commitment to translating scientific discoveries into effective clinical solutions that improve the quality of life for patients and caregivers worldwide.
We are excited to bring together global experts, emerging researchers, and dedicated practitioners to inspire innovation, spark meaningful dialogue, and foster partnerships that will shape the future of neurological healthcare.
Thank you for joining us in Paris for this vital gathering. Together, let us advance the frontiers of neuroscience and work towards a world free from the devastating impact of dementia and neurological diseases.
Warm regards,
Nancy Cassandra
Program Manager
Euro Dementia-2026
Euro Dementia-2026
About Conference
The 6th European Conference on Dementia, Alzheimers and Neurological Disorders is a premier international gathering dedicated to advancing research, clinical practice, and innovation in the fields of dementia, Alzheimer’s disease, and a broad spectrum of neurological disorders. This prestigious event in Paris, a global hub of scientific excellence, invites neurologists, neuroscientists, clinicians, researchers, healthcare professionals, and industry leaders to share the latest breakthroughs, evidence-based treatments, and cutting-edge technologies transforming patient care.
The conference provides a unique platform for multidisciplinary collaboration aimed at tackling the growing challenges posed by neurodegenerative diseases worldwide. Attendees will explore topics such as neuroinflammation, cognitive decline, biomarkers for early diagnosis, neuroimaging techniques, pharmacological and non-pharmacological interventions, genetic research, neurorehabilitation, and the impact of lifestyle and environmental factors on neurological health.
Why Attend?
-
Engage with leading experts presenting high-impact research and clinical advancements.
-
Discover innovative therapeutic strategies for Alzheimer’s and other dementias.
-
Network with top neurologists, neuroscientists, and healthcare innovators.
-
Participate in workshops focusing on patient care, dementia caregiving, and emerging diagnostics.
-
Contribute to shaping future policies and research directions in neurological disorders.
Join us in Paris to be at the forefront of neurological research and dementia care, fostering collaboration that accelerates breakthroughs and improves the lives of millions affected by these debilitating conditions.
Scientific Sessions/Tracks
We invite all neurologists, dementia researchers, clinicians, mental health professionals, and neuroscience experts to submit abstracts and register for the 6th European Conference on Dementia, Alzheimers and Neurological Disorders, scheduled for May 21–22, 2026, in Paris, France.
Ready to contribute? Choose from the scientific tracks below and submit your abstract today!
Explore the biochemical pathways and protein misfolding processes driving neurodegeneration and discover therapeutic targets at the molecular level.
Gain insights into the latest research breakthroughs, experimental therapies, and future directions in dementia and Alzheimer’s treatment.
Examine overlapping and distinct mechanisms in Parkinson’s, ALS, and Huntington’s Disease, along with clinical management strategies.
Understand the role of blood-based biomarkers, CSF analysis, and emerging digital biomarkers for early diagnosis and monitoring.
Learn how cutting-edge imaging tools like MRI and PET scans enhance diagnostic accuracy and help track disease progression.
Session on Cognitive Decline and Memory Impairment
Review assessment tools, diagnostic criteria, and interventions that address various forms of cognitive impairment and memory loss.
Delve into genetic predispositions, gene-environment interactions, and the promise of personalized medicine in dementia care.
Explore the link between chronic inflammation, microglial activation, and neurodegenerative disease progression.
Examine current FDA-approved medications and promising pharmacological developments in clinical trials.
Learn about behavioral therapies, memory training, and lifestyle-based interventions that enhance cognitive function.
Understand the impact of diet, exercise, stress, and exposure to pollutants on the risk and progression of neurological decline.
Gain expertise in designing clinical trials, evaluating endpoints, and translating laboratory findings into clinical applications.
Master evaluation techniques for symptoms like anxiety, apathy, delusions, and aggression in dementia patients.
Access evidence-based caregiving strategies, caregiver burden solutions, and holistic care frameworks.
Explore the mechanisms of healthy brain aging, neuroplasticity, and how some individuals maintain cognition despite pathology.
Understand neuroplasticity-based rehabilitation techniques to optimize recovery in aging and cognitively impaired patients.
Session on Sleep Disturbances and Cognitive Dysfunction
Examine the two-way relationship between sleep disorders and dementia, including sleep-based interventions and research.
Discover how AI, wearables, mobile apps, and predictive models are transforming early diagnosis and personalized care.
Address autonomy, informed consent, elder abuse, and data privacy in the context of dementia research and treatment.
Study how stroke, hypertension, and vascular disease contribute to cognitive deterioration and mixed dementia.
Understand how gut microbiota influence inflammation, brain health, and disease progression in dementia.
Review compassionate care approaches, symptom relief, communication strategies, and ethical dilemmas in advanced dementia.
Session on Early-Onset and Pediatric Dementia Syndromes
Explore rare, inherited, or metabolic disorders that lead to cognitive decline in children and younger adults.
Session on Neuropsychiatric Comorbidities in Dementia
Identify and manage mood, anxiety, psychotic, and obsessive-compulsive symptoms co-occurring with neurodegenerative conditions.
Learn about national dementia plans, global initiatives, funding models, and community-based outreach programs.
Submit your abstract and register today to share your research, exchange knowledge, and be part of a global movement to advance dementia and neurological disorder care.
Why to attend and who can attend?
Why to Attend?
The 6th European Conference on Dementia, Alzheimers and Neurological Disorders, taking place on May 21–22, 2026, in Paris, France, is a premier international platform dedicated to advancing the diagnosis, treatment, and care of dementia, Alzheimer’s disease, and other neurological disorders. This transformative event brings together the world’s leading neurologists, neuroscientists, geriatricians, psychiatrists, researchers, and healthcare professionals to share groundbreaking research, clinical innovations, and patient-centered care strategies.
Key Reasons to Attend:
- Discover Cutting-Edge Research: Gain access to the latest findings in neurodegenerative disease research, from biomarker discovery to neuroimaging and genetic advances.
- Explore Innovative Therapies: Learn about novel pharmacological and non-pharmacological treatment approaches reshaping dementia care.
- Engage in Multidisciplinary Dialogue: Connect with global experts across neurology, psychiatry, geriatrics, neuropsychology, and rehabilitation medicine.
- Enhance Your Clinical Practice: Update your knowledge with evidence-based strategies in cognitive assessment, early diagnosis, and long-term dementia care.
- Expand Your Professional Network: Collaborate with researchers, clinicians, policymakers, and industry leaders from across Europe, Asia, North America, and beyond.
- Present Your Research: Share your findings through oral or poster presentations, and gain international recognition.
- Experience Paris: Immerse yourself in rich culture and history while participating in one of Europe’s most influential medical conferences.
Whether you are a seasoned researcher or an early-career professional, this conference is your gateway to knowledge exchange, skill development, and global collaboration in the field of neurological and cognitive disorders.
Who Can Attend?
The conference is designed for a broad spectrum of professionals and academics working in neurology, neuroscience, mental health, and elderly care. It offers value for both clinical and research-focused participants.
Ideal Participants Include:
- Neurologists and Neuroscientists
- Geriatricians and Gerontologists
- Psychiatrists and Clinical Psychologists
- Alzheimer’s and Dementia Researchers
- Neuropsychologists and Cognitive Therapists
- Pharmacologists and Drug Development Experts
- Healthcare Professionals & Primary Care Providers
- Nursing Professionals and Caregivers
- Rehabilitation and Occupational Therapists
- Medical and Life Sciences Students
- Public Health Experts and Policy Makers
- AI, Digital Health, and Medical Technology Developers
- Industry Representatives from Biotech, Pharma, and Diagnostics
Whether you're involved in basic neuroscience, clinical care, public health, or technological innovation, this conference offers valuable opportunities to learn, collaborate, and lead in the global response to dementia and neurodegenerative disorders.
Visa Information
We warmly welcome all international attendees to join us in Paris, France for the 6th European Conference on Dementia, Alzheimers and Neurological Disorders, taking place on May 21–22, 2026. To ensure a smooth and hassle-free travel experience, we encourage all participants to begin their Schengen visa application process well in advance.
Do You Need a Visa to Attend?
If you are traveling from outside the Schengen Area or the European Union, you may be required to obtain a short-stay Schengen visa (Type C) for business or conference purposes. This visa typically allows stays of up to 90 days within a 180-day period.
Purpose of Visit: Attendance at a scientific/academic conference or seminar
Visa Type: Schengen Business/Conference Visa (Short-Stay Type C)
How We Support You
As a registered participant, you will be provided with the following supporting documents to facilitate your visa application:
- Official Letter of Invitation
- Conference Registration Confirmation
- Conference program/agenda
- Payment invoice or receipt
Please ensure you have completed your conference registration and payment to receive visa support documentation.
When to Apply?
We recommend that you apply for your visa at least 6–8 weeks before your intended travel date to allow ample processing time. Contact the French embassy or consulate in your country for exact requirements, appointment availability, and document checklists.
Required Documents (Typical List):
Valid passport (minimum 3 months validity after return date)
- Completed visa application form
- Passport-size photographs
- Proof of accommodation in France
- Travel itinerary or flight booking
- Travel insurance covering medical emergencies
- Proof of financial means (bank statements, sponsor letter, etc.)
- Invitation letter from the conference organizer
Schengen Visa Resources:
Official French Visa Portal: https://france-visas.gouv.fr/
Schengen Visa Info: https://www.schengenvisainfo.com/
Important Note:
The conference organizing committee is not authorized to intervene in visa decisions made by embassies or consulates. We strongly advise early application to avoid delays. If your visa is delayed or denied, please notify the organizing team promptly.
Need Assistance?
For help with visa-related questions or to request a personalized invitation letter, email us at:
Market Analysis
The global burden of dementia and Alzheimer’s disease is growing at an unprecedented rate, with millions of individuals and their families affected worldwide. The 6th European Conference on Dementia, Alzheimers and Neurological Disorders, scheduled for May 21–22, 2026, in Paris, France, serves as a strategic platform to address this critical healthcare challenge through interdisciplinary collaboration, innovation, and policy engagement.
Global Landscape
According to the World Health Organization (WHO), over 55 million people live with dementia globally, and this number is expected to reach 78 million by 2030 and 139 million by 2050. Alzheimer’s disease remains the most common form of dementia, accounting for 60–70% of all cases. The growing elderly population, increasing life expectancy, and rising public awareness are key factors contributing to the market’s expansion.
Dementia and Alzheimer’s Market Size
The global Alzheimer’s therapeutics market was valued at USD 6.3 billion in 2023 and is projected to surpass USD 14 billion by 2030, growing at a CAGR of 12.5%.
Europe holds a significant share of this market, driven by government funding, academic research excellence, and high disease prevalence in aging populations across countries like Germany, France, the UK, and Italy.
The neurological disorders drug market, covering Parkinson’s, ALS, and Huntington’s diseases, is also experiencing rapid growth due to increasing R&D investment and emerging biologics.
Key Growth Drivers
- Increased incidence of neurodegenerative disorders due to an aging population
- Accelerated development of biomarkers and diagnostic tools for early detection
- Rising use of AI, machine learning, and digital health technologies in dementia care
- Government initiatives and public-private partnerships for dementia awareness and prevention
- Expanding caregiver support and mental health services
- Industry and Research Opportunities
This conference offers immense value to:
- Pharmaceutical and biotech companies developing Alzheimer’s drugs and neurological treatments
- Medical device and digital health firms focused on diagnostics, wearables, and AI-driven tools
- Academic institutions and research labs engaged in dementia pathogenesis, clinical trials, and genomics
- Policy makers and healthcare administrators shaping public health strategies for cognitive aging
- Caregiver support organizations and geriatric health services enhancing quality of life for patients and families
Why Paris?
France is among the top European nations with a high incidence of dementia, with more than 1.2 million people affected. As a hub for neurological research, clinical trials, and public health policy, Paris offers the ideal setting for global stakeholders to convene, collaborate, and drive innovation forward in dementia care.
Be Part of a Growing Global Movement
By participating in the 6th European Conference on Dementia, Alzheimers and Neurological Disorders, you'll be part of a high-impact dialogue aimed at tackling one of the most urgent healthcare challenges of our time. Join leading voices in neurology, geriatrics, neuroscience, public health, and AI to explore how we can advance research, improve care delivery, and shape a dementia-ready future.
To Collaborate Scientific Professionals around the World
Conference Date May 21-22, 2026
For Sponsors & Exhibitors
Speaker Opportunity
Useful Links
Past Conference Report
Supported By
Journal of Alzheimers Disease & Parkinsonism
Brain Disorders & Therapy
Neurological Disorders
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by